1. Academic Validation
  2. Persistent insulin signaling coupled with restricted PI3K activation causes insulin-induced vasoconstriction

Persistent insulin signaling coupled with restricted PI3K activation causes insulin-induced vasoconstriction

  • Am J Physiol Heart Circ Physiol. 2019 Nov 1;317(5):H1166-H1172. doi: 10.1152/ajpheart.00464.2019.
T Dylan Olver 1 Zachary I Grunewald 2 3 Thaysa Ghiarone 3 Robert M Restaino 3 4 Allan R K Sales 3 5 6 Lauren K Park 2 3 Pamela K Thorne 7 Rama Rao Ganga 8 Craig A Emter 7 Peter W R Lemon 9 J Kevin Shoemaker 9 Camila Manrique-Acevedo 3 10 11 Luis A Martinez-Lemus 3 12 Jaume Padilla 2 3
Affiliations

Affiliations

  • 1 Department of Biomedical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatchewan, Canada.
  • 2 Department of Nutrition and Exercise Physiology, University of Missouri, Columbia, Missouri.
  • 3 Dalton Cardiovascular Research Center, University of Missouri, Columbia, Missouri.
  • 4 Department of Health and Human Physiological Sciences, Skidmore College, Saratoga Springs, New York.
  • 5 Heart Institute (InCor), University of São Paulo Medical School, São Paulo, Brazil.
  • 6 D'Or Institute for Research and Education, São Paulo, Brazil.
  • 7 Department of Biomedical Sciences, University of Missouri, Columbia, Missouri.
  • 8 Department of Surgery, University of Missouri, Columbia, Missouri.
  • 9 School of Kinesiology, The University of Western Ontario, London, Ontario, Canada.
  • 10 Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Missouri, Columbia, Missouri.
  • 11 Research Services, Harry S. Truman Memorial Veterans Hospital, Columbia, Missouri.
  • 12 Department of Medical Pharmacology and Physiology, University of Missouri, Columbia, Missouri.
Abstract

Insulin modulates vasomotor tone through vasodilator and vasoconstrictor signaling pathways. The purpose of the present work was to determine whether insulin-stimulated vasoconstriction is a pathophysiological phenomenon that can result from a combination of persistent Insulin signaling, suppressed phosphatidylinositol-3 kinase (PI3K) activation, and an ensuing relative increase in MAPK/endothelin-1 (ET-1) activity. First, we examined previously published work from our group where we assessed changes in lower-limb blood flow in response to an oral glucose tolerance test (endogenous Insulin stimulation) in lean and obese subjects. The new analyses showed that the peak rise in vascular resistance during the postprandial state was greater in obese compared with lean subjects. We next extended on these findings by demonstrating that insulin-induced vasoconstriction in isolated resistance arteries from obese subjects was attenuated with ET-1 receptor antagonism, thus implicating ET-1 signaling in this constriction response. Last, we examined in isolated resistance arteries from pigs the dual roles of persistent Insulin signaling and blunted PI3K activation in modulating vasomotor responses to Insulin. We found that prolonged Insulin stimulation did not alter vasomotor responses to Insulin when insulin-signaling pathways remained unrestricted. However, prolonged insulinization along with pharmacological suppression of PI3K activity resulted in insulin-induced vasoconstriction, rather than vasodilation. Notably, such aberrant vascular response was rescued with either MAPK inhibition or ET-1 receptor antagonism. In summary, we demonstrate that insulin-induced vasoconstriction is a pathophysiological phenomenon that can be recapitulated when sustained Insulin signaling is coupled with depressed PI3K activation and the concomitant relative increase in MAPK/ET-1 activity.NEW & NOTEWORTHY This study reveals that insulin-induced vasoconstriction is a pathophysiological phenomenon. We also provide evidence that in the setting of persistent Insulin signaling, impaired phosphatidylinositol-3 kinase activation appears to be a requisite feature precipitating MAPK/endothelin 1-dependent insulin-induced vasoconstriction.

Keywords

MAPK; diabetes; endothelin-1; obesity; selective insulin resistance.

Figures
Products